Gardasil For Males Gets FDA OK; Next Up, Cost-Effectiveness Questions
Executive Summary
Merck's Gardasil human papillomavirus vaccine is headed back for a key review by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices on Oct. 21 with FDA's safety and efficacy approval in hand
You may also be interested in...
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.